Professional Career
- 2020-Present, a member of Global Pharma Key Opinion Leader (GPKOL) for CMC/cGMP, Korea Health Industry Development Institute
- 2020-Present: ILIAS Biologics, Chief Technology Officer, Daejeon, Korea
Development of innovative exosome-based therapies that use exosomes as carriers for intracellular protein delivery.
- 2017-2019: Helixmith, SVP/Head of CMC, Seoul, Korea
Development of gene therapies for neuromuscular diseases using plasmid DNA.
- 2006-2017: US FDA/CDER/Office of Biotechnology Products, Maryland, USA
Worked as a CMC reviewer for biotech and biosimilar product reviews
Participated in cGMP manufacturing facility inspections.
- 1999-2006: US DOD, Edgewood Chemical Biological Center, Maryland, USA
Research on biologic agents and small-scale production of proteins, monoclonal antibodies, and enzymes.
- 1989-1999: Alpha-Beta Technology, Massachusetts, USA
Development of carbohydrate-based therapies for immunomodulator or wound healing, etc.
Education:
- Worcester Polytechnic Institute, Ph.D., Biochemical Engineering, Massachusetts, USA
- KAIST, MS, Chemical Engineering, Seoul, Korea
- Yonsei University, BS, Chemical Engineering, Seoul, Korea